SCHEMBL5881802

SCHEMBL5881802

Cc1[nH]c2ccc(C(=O)O)cc2c1Cc1ccncc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.54
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 2/20 0.49
THRB P10828 1/20 0.49
HPGD P15428 1/20 0.49
PSMD14 O00487 1/20 0.48
RECQL P46063 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
APEX1 P27695 1/20 0.48
TBXAS1 P24557 2/20 0.47
POLB P06746 2/20 0.44
PARP1 P09874 1/20 0.43
CSNK2A1 P68400 1/20 0.43
PTGS2 P35354 1/20 0.42
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882142 0.88 KDM4E (0.48) PTPN5KDM4EALDH1A1HPGDTBXAS1
SCHEMBL5881790 0.84 PTPN5 (0.58) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5881620 0.83 PTPN5 (0.57) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6326442 0.81 PTPN5 (0.55) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5881650 0.81 PTPN5 (0.55) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5882016 0.80 PPARG (0.43) PTPN5KDM4EPSMD14RECQLRXFP1
SCHEMBL5881662 0.79 PTPN5 (0.53) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6326861 0.78 PTPN5 (0.52) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6322652 0.78 POLB (0.61) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6319379 0.77 PTPN5 (0.50) PTPN5KDM4EALDH1A1THRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT PTPN5 2703/4885KDM4E 2944/4885ALDH1A1 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.